Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PPP001 vs Oral Opioids for Breakthrough Cancer Pain
NCT03564548Phase 2Unknown
- Sponsor
- Tetra Bio-Pharma Inc.
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of qixleef in breakthrough cancer pain (BTcP), sponsored by Tetra Bio-Pharma Inc.. Status: unknown.
02
Drugs
qixleef
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT03564548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564548.